A multinational randomized trial led by Voors et al. revealed that empagliflozin, an SGLT2 inhibitor, substantially decreased the risk of cardiovascular events, mortality, and heart failure, while also improving the overall quality of life in patients suffering from acute heart failure. The gene discussed is SLC5A2; the disease is heart failure.